INFORMATION BY CANCER TYPE

Immuno oncology

Glioblastoma Vaccine to Be Tested as Orphan Drug, Easing Clinical Trials Process
BY Thomas Keenan
The designation recognizes that the vaccine, an immunotherapy called SurVaxM, would treat a rare disease, defined as one that affects a patient population of less than 200,000 Americans. However, because it acts on a protein that appears in 80 percent of cancers generally, SurVaxM may have wider applications.  
Immunotherapy Treatment Advances in Anal Cancer
BY Meeri Kim
More personalized approaches are being developed to treat patients with metastatic disease.
When Cancer Says
BY Kelly Irvin
Scoring the big NED often leads to that "Terminator" voice whispering in your ear.
FDA Approves Yervoy for Pediatric Melanoma Population
BY Jason M. Broderick
Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
Combination Immunotherapy Being Investigated in Advanced Melanoma
BY Ariela Katz
A study pairs an IDO inhibitor with PD-1 checkpoint blockade.
Immunotherapy Combination Is Active in Patients With Melanoma Brain Metastases
BY Jason M. Broderick
Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO. 
Using a Virus to Boost Immunotherapy Response in Melanoma
BY Lauren M. Green
Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.
How I Remember
BY Diana M. Martin
A plan for remembering your loved one when times get tough.
FDA Approves Bavencio for Bladder Cancer
BY Jason M. Broderick
The Food and Drug Administration has granted an accelerated approval to the PD-L1 inhibitor Bavencio (avelumab) for the treatment of patients with locally advanced or metastatic urothelial carcinoma.
Tecentriq Approved as First-Line Treatment for Some Patients With Bladder Cancer
BY Jason Broderick
The FDA has granted an accelerated approval to Tecentriq as a frontline treatment for patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin chemotherapy.
Special Feature
Share Your Art
Talk about this article with other patients, caregivers, and advocates in the Immuno-oncology CURE discussion group.
Search Cancer Drugs & Terms
x